Cargando…
Small-molecule Bcl-2 antagonists as targeted therapy in oncology
Dynamic protein–protein interactions between proapoptotic and pro-survival Bcl-2 family members regulate outer-mitochondrial membrane permeabilization and cytochrome c release, key events in the path to apoptosis. Their relative levels often dictate the fate of a cell following an apoptotic stimulus...
Autores principales: | Warr, M.R., Shore, G.C. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Multimed Inc.
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2601021/ https://www.ncbi.nlm.nih.gov/pubmed/19079626 |
Ejemplares similares
-
Development of cell-cycle inhibitors for cancer therapy
por: Dickson, M.A., et al.
Publicado: (2009) -
Novel developments in angiogenesis cancer therapy
por: Hirte, H.W.
Publicado: (2009) -
rna interference and micro rna –oriented therapy in cancer: rationales, promises, and challenges
por: Duchaine, T.F., et al.
Publicado: (2009) -
Targeting mtor-dependent tumours with specific inhibitors: a model for personalized medicine based on molecular diagnoses
por: Furic, L., et al.
Publicado: (2009) -
Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)